China's Biotech Ambitions Threaten US Drug Supply Security

• •China aims for 25% of global first-in-class drugs by 2030 under its new five-year plan.
• •The U.S. imports 90% of its pharmaceutical inputs, primarily from China and India.
• •Experts warn that China's biotech dominance could threaten U.S. health security.

China has launched a new five-year plan aiming to dominate the global biomedicine market by 2030, targeting at least 25% of the world's first-in-class drugs. This initiative is part of a broader strategy to enhance its biotechnology sector, which is already making significant strides, with Chinese-designed medicines accounting for nearly 30% of global drug development as of 2025. The U.S. remains heavily reliant on China for pharmaceutical ingredients, with 90% of inputs for prescription drugs imported, primarily from China and India. Experts warn that if China achieves its biotech goals, it could leverage this dominance against U.S. health and security interests. The U.S. must invest in its biotech capabilities to counter this growing threat and maintain its leadership in drug innovation. Recent discussions in Washington have focused on potential trade restrictions to slow China's progress, but there are concerns that broad measures could harm U.S. interests instead.